Is NWBO, CLDX or IMUC a good stock option to invest into or are these stocks a immediate doomsday once you invest.

1. Nwbo, Cldx and Imuc,
should you invest.
Analysis by Aaron Golbin
All information is accurate as of December 24, 2014

2. Executive summary
Is NWBO, CLDX or IMUC a good stock option to invest into or are these
stocks a immediate doomsday once you invest.
 NWBO stock chart with a range of 3 years and background on NWBO
 IMUC stock chart for 3 years and a background on CLDX.
 CLDX stock chart for 3 years and background on IMUC.
All information is accurate as of December 24, 2014 and information is taken from yahoo.com/finance, but not directly copied. The information contained in
this e-mail, and any attachment, is confidential and is intended solely for the use of the intended recipient. Access, copying or re-use of the e-mail or any
attachment, or any information contained therein, by any other person is not authorized. If you are not the intended recipient please return the e-mail to
the sender and delete it from your computer. Although we attempt to sweep e-mail and attachments for viruses, we do not guarantee that either are virus-
free and accept no liability for any damage sustained as a result of viruses.
Please refer to aaron.golbin@Hotmail.com if you are a disclaimer.

3. NWBO only gains 6 cents per Share in 3 years.
All information is accurate as of December 24, 2014
5.44
3.68
7.87
3.12
3.52 3.5 3.37
3.77
7.69
6.71
4.83
5.5
0
2
4
6
8
10
Q1/2012 Q2/2012 Q3/2012 Q4/2012 Q1/2013 Q2/2013 Q3/2013 Q4/2013 Q1/2014 Q2/2014 Q3/2014 Q4/2014
NWBO
Series 1 2 per. Mov. Avg. (Series 1)

4. about NWBO
NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor
cancers more effectively than current treatments, and without the side effects of
chemotherapy drugs. NW Bio’s proprietary manufacturing technology enables the
Company to produce its personalized vaccine in an efficient, cost-effective manner. The
Company has a broad platform technology for DCVax dendritic cell-based vaccines. The
Company’s lead product, DCVax-L, is currently in a 348-patient Phase III trial for patients
with newly diagnosed Glioblastoma multiform (GBM), the most aggressive and lethal brain
cancer. The Company’s second product, DCVax-Direct, is currently in a 60-patient Phase
I/II trial for direct injection into all types of inoperable solid tumor cancers. The Company
has also conducted a Phase I/II trial with DCVax for late stage ovarian cancer together with
the University of Pennsylvania. The Company previously received clearance from the FDA
for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage
prostate cancer.
Taken from http://www.nwbio.com/about-us/. All right reserved.
All information is accurate as of December 24, 2014

5. strengths opportunities
• Many developing vaccines in testing phases.
• Some vaccines already FDA approved.
• DCVax-L being released soon, a vaccine for a form
of brain cancer.
• Developing medicines in testing phases.
• Being approved and used at many hospitals and
medical centers.
• Getting through testing phases of developing
medicines faster.
weaknesses threats
• This Company Does Not Have Major Growth For A
Company Of It’s Size.
• Spectrum Inc. to be approved by the FDA with
their new drug in the same area as NWBO
vaccines.
• Oncegenex Inc. passes FDA tests with their drug in
the same industry as NWBO vaccines.

6. Taken from http://www.nwbio.com/product-candidates/ and edited by Aaron golbin.
All information is accurate as of December 24, 2014
DCVax-L
DCVax-L — is made with cancer antigens from tumor lysate (a protein extract from
processed tumor cells) from the patient’s own tumor tissue. As such, DCVax-L
incorporates the full set of tumor antigens, making it difficult for tumors to find ways
around it (“escape variants”), as described above. This is the DCVax product that has
been used in our GBM brain cancer and ovarian cancer clinical trials, and is currently
in our Phase III trial. DCVax-L is expected to be used for any solid tumor cancers in
situations in which the patient has their tumor surgically removed as part of standard
of care.
Their Current Phase III Trial
They are currently conducting a 348-patient double blind, randomized, placebo controlled Phase III clinical trial
with DCVax-L for newly diagnosed GBM. The primary endpoint of the trial is “Progression Free Survival,”
meaning the length of time that a patient continues without disease progression (i.e., recurrence of the tumor).
Secondary endpoints include overall survival and other measures.
The trial is under way at 50+ sites (medical centers) across the US. The sites and the eligibility criteria are
listed in the profile of the trial at ClinicalTrials.gov. The trial is also under way in Europe. The lead site is Kings
College Hospital in London. Approximately 30 trial sites are also in varying stages of preparation in the U.K.
and Germany.
DCVax-L about and trials(phase 111)

7. In a 3 year period IMUC gains about 2.30 a share, witch is horrible compared to their
direct rivals such as CLDX.
All information is accurate as of December 24, 2014
2.99
3.75
2.8
1.92
2.59
1.97
2.65
0.93
1.24 1.13
0.85
0.67
0
1
2
3
4
Q1/2012 Q2/2012 Q3/2012 Q4/2012 Q1/2013 Q2/2013 Q3/2013 Q4/2013 Q1/2014 Q2/2014 Q3/2014 Q4/2014
imuc
imuc 2 per. Mov. Avg. (imuc)

8. About IMUC
Immuno Cellular therapeutics ltd. Is a clinical-stage biotechnology company that is
developing novel cancer vaccine immunotherapies for the treatment of brain, ovarian
and other solid tumors. MARKET CAP- 42.02 million.
strength opurtunities
• Exclusive next-generation technology available
to IMUC.
• Releases of currently developing vaccines and
drugs.
• Advanced manufacturing allows the production
and storage of multiple vaccine doses from one
process.
• Expanding to many cancer and medical facilities
internationaly.
• Major research in this field. • Develop speed level of research and the
process of creating vaccines.
weakness threats
• Beating competition on speed level of creating
vaccines and distribution.
• Slowing down developing process of vaccines.

9. CLDX grew more then 3 times in 3 years, witch is very good in the biotech industry.
All information is accurate as of December 24, 2014
5.19 5.47 6.38 6.71
11.51
16.36
37.83
The price dropped
because, of a major loss
in money due to failed
research.(more info in
slide 8.17.94 17.32
12.37
18.24
0
10
20
30
40
Q1/2012 Q2/2012 Q3/2012 Q4/2012 Q1/2013 Q2/2013 Q3/2013 Q4/2013 Q1/2014 Q2/2014 Q3/2014 Q4/2014
cldx
cldx Linear (cldx)

10. Celldex’s Financial Report Is An Investor’s
Worst Nightmare
Category title 2010 2011 2012 2013
revenue 11.2 million 9.3 million 11.2 million 4.1 million
Operating
income
- 37.0 million - 43.4 million - 48.1 - 81.4

11. about CLDX
Celldex is developing targeted therapeutics to address devastating diseases. Their pipeline is
built from a proprietary portfolio of antibodies and immunomodulators used alone and in
strategic combinations to create novel, disease-specific therapies that induce, enhance or
suppress the body's immune response. MARKET CAP- 1.63B
strengths oppurtunities
• A lot of candidates in late phase
testing.
• Getting drugs distributed to a
chained hospital.
• Very good and effective drugs. • Getting medicines through testing
faces for distribution.
• Developing drugs on the way.
weaknesses threats
• Not successfully being able to go
ahead of their competitors.
• Slow process of getting medicines
through the testing phases.

12. conclusion
Based on my research I found that…
 CLDX has a 1.43 billion dollar market cap and in over 3 years the stock tripled.
 NWBO only grew 6 cents per share over three years.
 IMUC are struggling to catch up to their direct competitor CLDX, and have a
smaller market cap then most of their competitors.
For these reasons I do not recommend investing in NWBO or IMUC and only
recommend investing in CLDX.